El consorci format per aptaTargets, l’Institut de Recerca Biom\u00e8dica de Bellvitge (IDIBELL), l’Institut de Recerca Germans Trias i Pujol (IGTP), la Universitat de Valladolid i l’Institut de Recerca Vall d’Hebron (VHIR) ha rebut 4 milions de euros de finan\u00e7ament del Ministeri de Ci\u00e8ncia i Innovaci\u00f3 d’Espanya mitjan\u00e7ant l’Ag\u00e8ncia Estatal de Recerca (AEI).<\/p>\n
<\/p>\n
La subvenci\u00f3 recolzar\u00e0 el projecte NexTOLL, que t\u00e9 per objectiu llan\u00e7ar un assaig cl\u00ednic multic\u00e8ntric de fase 2b per confirmar l’efecte neuroprotector d’ApTOLL en pacients amb accident cerebrovascular isqu\u00e8mic agut (AIS). L’assaig cl\u00ednic est\u00e0 previst que comenci el 2024 i Pere Cardona, investigador principal del grup de recerca de Malalties Neurol\u00f2giques i Neurogen\u00e8tica<\/a> de l’IDIBELL i director del Programa Neurovascular i de la Unitat d’Ictus<\/a> de l’Hospital Universitari de Bellvitge, estar\u00e0 entre els neur\u00f2legs que el portaran a terme.<\/p>\n <\/p>\n Aquests fons sorgeixen d’una convocat\u00f2ria altament competitiva del Programa Estatal per al Foment de la Investigaci\u00f3 Cient\u00edfica i T\u00e8cnica i la seva Transfer\u00e8ncia 2022 (anteriorment conegut com a Reptes Col\u00b7laboraci\u00f3) que preveu finan\u00e7ament per a projectes de col\u00b7laboraci\u00f3 publicoprivada per catalitzar la innovaci\u00f3 i el lideratge empresarial a petites empreses i mitjanes empreses (PIMES).<\/p>\n <\/p>\n Els resultats de la investigaci\u00f3 realitzada amb ApTOLL fins ara s\u00f3n molt encoratjadors. Es tracta del primer f\u00e0rmac neuroprotector que obt\u00e9 resultats positius en assajos cl\u00ednics<\/a> amb pacients, els quals es van presentar a la International Stroke Conference 2023 i es van publicar a la prestigiosa revista cient\u00edfica JAMA Neurology<\/a>.<\/p>\n <\/p>\n El finan\u00e7ament rebut de l’AEI \u00e9s clau per portar ApTOLL al mercat, que podria proporcionar una opci\u00f3 terap\u00e8utica important per als pacients amb accident cerebrovascular que tenen una necessitat m\u00e8dica important no coberta.<\/p>\n <\/p>\n Un assaig cl\u00ednic de fase IIb per avaluar lefecte neuroprotector dApTOLL en pacients amb accident cerebrovascular. NextTOLL CPP2022-009778.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" \u00c8xit col\u00b7laboratiu en l’aven\u00e7 de la neuroprotecci\u00f3 contra accidents cerebrovasculars<\/p>\n","protected":false},"author":8,"featured_media":24943,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[416,340,446,457],"tags":[],"class_list":["post-24942","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-malalties-neurologiques-i-neurogenetica","category-neurociencies","category-noticies","category-p-de-neurociencies"],"publishpress_future_action":{"enabled":false,"date":"2024-11-29 08:40:11","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=24942"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24942\/revisions"}],"predecessor-version":[{"id":24948,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24942\/revisions\/24948"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/24943"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=24942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=24942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=24942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}